OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
OSR Holdings (NASDAQ:OSRH) entered a definitive global exclusive license with BCM Europe for Phase‑3 ready oral immunotherapy VXM01, creating up to $815 million in milestone payments and acquiring VXM01 IP for $30 million.
Rhea-AI Summary
OSR Holdings (NASDAQ:OSRH) entered a definitive global exclusive license with BCM Europe for Phase‑3 ready oral immunotherapy VXM01, creating up to $815 million in milestone payments and acquiring VXM01 IP for $30 million. BCME pledged ~29.7% of OSRH shares as collateral and a $15 million put option at $10.00/share is included. Governing law: Canton of Basel, Switzerland. Independent directors approved the related‑party deal after a fairness opinion.
Positive
- Potential up to $815 million in milestone payments
- OSRH to acquire VXM01 IP for $30 million
- BCME pledged ~29.7% of OSRH shares as collateral
- 100% downstream royalties to OSRH after BCME recovery
- Put option for up to $15 million at $10.00/share
Negative
- Related‑party transaction with largest shareholder (potential governance scrutiny)
- Milestone payments depend on future clinical, regulatory, and commercial success
- BCME must recover investment before OSRH receives downstream royalties
- Collateral pledge could concentrate voting risk if enforcement occurs
Details
News Market Reaction – OSRH
In the Apr 29 session, OSRH declined 38.19%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- VXM01 stage
- Phase 3-ready
- Oral immunotherapy targeting VEGFR-2
- Milestone potential
- $815 million
- Clinical, regulatory, and commercial milestones under VXM01 agreement
- VXM01 IP purchase
- $30 million
- Asset purchase agreement to acquire full VXM01 IP from Vaximm AG
- Royalty entitlement
- 100% downstream royalties
- After BCME recovers its investment and preferred return
- Equity pledge stake
- 29.7%
- BCME and affiliates’ OSRH shareholding pledged as collateral at signing
- Put option size
- $15 million
- Maximum OSRH common stock BCME may be required to purchase
- Put option price
- $10.00 per share
- Exercise price, exercisable no earlier than six months after effective date
Historical Context
-
Convertible note used to eliminate warrant overhang and reduce dilution risk.
-
Conference presentation to review milestones for VXM01 and Woori IO platform.
-
Flash report reaffirmed rating and highlighted VXM01 and Woori IO opportunities.
-
Updated VXM01 license terms with up to $815M milestones payable to OSRH.
-
Woori IO signed NDA with Sinopharm to explore China and global trials.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
immunotherapy medical
put option financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders
BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has entered into a definitive global exclusive license agreement (the "Agreement") with BCM Europe AG ("BCME") for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2.
The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across OSRH, its largest shareholder BCME, and public shareholders.
"This agreement establishes a clear, accountable framework for the development of VXM01," said Peter Hwang, CEO of OSRH. "It ensures OSR Holdings shareholders participate directly in value creation, while BCME remains accountable for its financial commitments."
Transaction Overview
License: BCME receives an exclusive global license to develop, manufacture, commercialize, and sublicense VXM01
Milestones: OSRH to receive up to
$815 million in milestone payments tied to clinical, regulatory, and commercial achievementsIP Ownership: OSRH to acquire full VXM01 IP from Vaximm AG under a
$30 million asset purchase agreementRoyalties: OSRH to receive
100% of downstream royalties after BCME recovers its investment and preferred returnSecurity: BCME and affiliates pledge
100% of their OSRH shares as collateral for milestone obligationsGoverning Law: Switzerland (Canton of Basel)
BCME is the Company's largest shareholder. Accordingly, the Agreement constitutes a related party transaction and was approved by the Board, including independent directors, following consideration of an independent fairness opinion provided by Avance Life Sciences.
Taken together, these economics position OSRH to capture the long-term value created through VXM01's development and commercialization.
Alignment Through Equity Pledge
Under a separate Pledge Agreement, BCME and affiliates have pledged their entire unencumbered shareholding in OSRH, representing approximately
Provide assurance of BCME's financial commitments under the Agreement
Align the economic interests of the largest shareholder with those of public shareholders
Support milestone performance through a collateral-backed mechanism under the Pledge Agreement
"The decision by BCME to pledge its entire stake as collateral reflects strong conviction in the clinical and commercial potential of VXM01," said Tim Smith, Head of Investor Relations. "It aligns all shareholders around advancing this program toward commercialization and delivering meaningful new treatment options to patients."
BCME will actively support development of VXM01 and at the same time engage leading global pharmaceutical partners to secure a sublicensing transaction. With economic returns dependent on downstream monetization and its entire OSRH stake pledged as collateral, BCME is structurally incentivized to advance VXM01 and execute a competitive partnering process focused on maximizing value for OSRH shareholders.
Additional Value Mechanism: Put Option
The Agreement also includes a put option under which OSRH may require BCME to purchase up to
About VXM01
VXM01 is a clinical-stage oral immunotherapy targeting VEGFR-2, designed to induce a targeted immune response against tumor vasculature and modulate the tumor microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies in glioblastoma and pancreatic cancer, two of the most aggressive and treatment-resistant solid tumors. VXM01 is being developed by Vaximm AG, a wholly owned subsidiary of OSR Holdings.
About BCM Europe AG
BCM Europe AG is a Switzerland-based life sciences investment entity and the largest shareholder of OSR Holdings.
About OSR Holdings
OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.
Investor Contact
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding expected development, milestone payments, sublicensing activities, and the potential benefits of the Agreement. These statements are subject to risks and uncertainties, including clinical, regulatory, and market risks, and actual results may differ materially. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.
SOURCE: OSR Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.